false 0001055726 0001055726 2026-11-13 2026-11-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 13, 2026
Inovio Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
| Delaware |
|
001-14888 |
|
33-0969592 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
| 660 W. Germantown Pike Suite 110 |
| Plymouth Meeting, PA 19462 |
| (Address of principal executive offices, including zip code) |
(267) 440-4200
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, $0.001 par value |
|
INO |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective November 13, 2026, the Board of Directors (the “Board”) of Inovio Pharmaceuticals, Inc. (the “Company”) increased the size of the Board from eight to nine directors and appointed Jeffrey Libson to fill the newly created directorship. Mr. Libson will hold office until the Company’s 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier death, resignation or removal. Effective November 13, 2026, Mr. Libson was also appointed as a member of the Company’s Finance Committee.
Mr. Libson (age 72) has served as a mentor and strategic advisor to the Company since January 2025. From December 2016 to January 2025, Mr. Libson was a partner at Cooley LLP and a member of its Global Life Sciences Leadership Team, advising life sciences companies, boards, entrepreneurs and investors. Previously, he was a partner and head of the life sciences practice at Pepper Hamilton LLP, where he served from August 1981 to December 2016. From September 2006 to January 2025, Mr. Libson also served as an adjunct professor at The Wharton School of the University of Pennsylvania, teaching a graduate-level course in life sciences entrepreneurship. He has served as a member of the board of trustees of the Sabin Vaccine Institute since May 2020 and of Eastern University since February 2026. Mr. Libson holds a BA in Economics and English from Oberlin College and a J.D. from the Duke University School of Law. The Board believes that Mr. Libson’s extensive experience advising life sciences companies and their boards, his expertise in life sciences entrepreneurship and his service on nonprofit boards qualify him to serve on our Board.
In connection with his appointment as director, Mr. Libson will participate in the Company’s Non-Employee Director Compensation Program, including an annual cash retainer of $45,000 for service as a Board member and an additional annual cash retainer of $5,000 for service as a Finance Committee member, payable and prorated in accordance with the terms of that program. Mr. Libson will also receive equity awards in the future in accordance with the terms of the Company’s Non-Employee Director Compensation Program.
There are no family relationships between Mr. Libson and any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Libson and any other person pursuant to which either was appointed as a director of the Company. Mr. Libson is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
In connection with his appointment as director, Mr. Libson will enter into the Company’s standard form of indemnification agreement for its executive officers and directors, a copy which was filed as Exhibit 10.1 to the Company’s Quarterly Report on form 10-Q (File No. 001-14888) filed with the SEC on August 19, 2009.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
INOVIO PHARMACEUTICALS, INC. |
|
|
|
|
| Date: November 17, 2026 |
|
|
|
|
|
/s/ Peter Kies |
| |
|
|
|
|
|
Peter Kies |
| |
|
|
|
|
|
Chief Financial Officer |